The Office of Health Economics held a workshop last year with companies that presented their business and incentivization models: BAE Systems (defence), Allianz (insurance), Barclays Bank (finance), EDF Energy (energy), Dun & Bradstreet (corporate information) and Knowledge Unlatched (academic publishing). These models were then explored further for their applicability to antibiotics R&D.
Key points & recommendations from the workshop:
– There is a need for consolidated and focused research of antibiotic R&D. “There is a need for a an entity that pools resources, science and compounds; one that is sustainable and independent with focus on the research and early development of antibiotics in line with predefined public health-need profiles. This entity should find a way to open up the science to all working in this area.”
– The creation of a global funding vehicle putting together the resources from multiple companies, academic institutions and public bodies, in order to fund the appropriate research, early development and good stewardship of antibiotics.
– The implementation of new commercial business model for antibiotics delinked from price/volume.
Find out more: New Business Models for Antibiotics